Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Correction to: Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.

Mavroeidi P, Arvanitaki F, Karakitsou AK, Vetsi M, Kloukina I, Zweckstetter M, Giller K, Becker S, Sorrentino ZA, Giasson BI, Jensen PH, Stefanis L, Xilouri M.

Acta Neuropathol. 2019 Sep 3. doi: 10.1007/s00401-019-02068-y. [Epub ahead of print]

PMID:
31485733
2.

Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression.

Sorrentino ZA, Goodwin MS, Riffe CJ, Dhillon JS, Xia Y, Gorion KM, Vijayaraghavan N, McFarland KN, Golbe LI, Yachnis AT, Giasson BI.

Acta Neuropathol Commun. 2019 Sep 2;7(1):142. doi: 10.1186/s40478-019-0787-2.

3.

An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes.

Futch HS, McFarland KN, Moore BD, Kuhn MZ, Giasson BI, Ladd TB, Scott KA, Shapiro MR, Nosacka RL, Goodwin MS, Ran Y, Cruz PE, Ryu DH, Croft CL, Levites Y, Janus C, Chakrabarty P, Judge AR, Brusko TM, de Kloet AD, Krause EG, Golde TE.

J Exp Med. 2019 Aug 29. pii: jem.20190430. doi: 10.1084/jem.20190430. [Epub ahead of print]

PMID:
31467037
4.

Exploring the Peripheral Initiation of Parkinson's Disease in Animal Models.

Sorrentino ZA, Giasson BI.

Neuron. 2019 Aug 21;103(4):547-549. doi: 10.1016/j.neuron.2019.07.031.

PMID:
31437447
5.

Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.

Koller EJ, De La Cruz EG, Machula T, Ibanez KR, Lin WL, Williams T, Riffe CJ, Ryu D, Strang KH, Liu X, Janus C, Golde TE, Dickson D, Giasson BI, Chakrabarty P.

Hum Mol Genet. 2019 Jul 1. pii: ddz151. doi: 10.1093/hmg/ddz151. [Epub ahead of print]

PMID:
31261380
6.

Comparative analyses of the in vivo induction and transmission of α-synuclein pathology in transgenic mice by MSA brain lysate and recombinant α-synuclein fibrils.

Dhillon JS, Trejo-Lopez JA, Riffe C, Levites Y, Sacino AN, Borchelt DR, Yachnis AY, Giasson BI.

Acta Neuropathol Commun. 2019 May 20;7(1):80. doi: 10.1186/s40478-019-0733-3.

7.

Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.

Mavroeidi P, Arvanitaki F, Karakitsou AK, Vetsi M, Kloukina I, Zweckstetter M, Giller K, Becker S, Sorrentino ZA, Giasson BI, Jensen PH, Stefanis L, Xilouri M.

Acta Neuropathol. 2019 Sep;138(3):415-441. doi: 10.1007/s00401-019-02014-y. Epub 2019 Apr 22. Erratum in: Acta Neuropathol. 2019 Sep 3;:.

PMID:
31011860
8.

α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.

Sorrentino ZA, Giasson BI, Chakrabarty P.

Acta Neuropathol. 2019 Jul;138(1):1-21. doi: 10.1007/s00401-019-01977-2. Epub 2019 Feb 23. Review.

PMID:
30798354
9.

rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.

Croft CL, Cruz PE, Ryu DH, Ceballos-Diaz C, Strang KH, Woody BM, Lin WL, Deture M, Rodríguez-Lebrón E, Dickson DW, Chakrabarty P, Levites Y, Giasson BI, Golde TE.

J Exp Med. 2019 Mar 4;216(3):539-555. doi: 10.1084/jem.20182184. Epub 2019 Feb 15.

10.

MAPT mutations, tauopathy, and mechanisms of neurodegeneration.

Strang KH, Golde TE, Giasson BI.

Lab Invest. 2019 Jul;99(7):912-928. doi: 10.1038/s41374-019-0197-x. Epub 2019 Feb 11. Review.

PMID:
30742061
11.

Dissecting α-synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis.

Dhillon JS, Trejo-Lopez JA, Riffe C, McFarland NR, Hiser WM, Giasson BI, Yachnis AT.

Lab Invest. 2019 Jul;99(7):982-992. doi: 10.1038/s41374-019-0198-9. Epub 2019 Feb 8. Review.

PMID:
30737468
12.

Phosphorylation of serine 305 in tau inhibits aggregation.

Strang KH, Sorrentino ZA, Riffe CJ, Gorion KM, Vijayaraghavan N, Golde TE, Giasson BI.

Neurosci Lett. 2019 Jan 23;692:187-192. doi: 10.1016/j.neulet.2018.11.011. Epub 2018 Nov 10.

PMID:
30423399
13.

Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Sorrentino ZA, Vijayaraghavan N, Gorion KM, Riffe CJ, Strang KH, Caldwell J, Giasson BI.

J Biol Chem. 2018 Dec 7;293(49):18914-18932. doi: 10.1074/jbc.RA118.005603. Epub 2018 Oct 16.

PMID:
30327435
14.

Designing antibodies against LRRK2-targeted tau epitopes.

Hamm M, Ladd TB, Levites Y, Golde TE, Giasson BI, Lewis J.

PLoS One. 2018 Sep 27;13(9):e0204367. doi: 10.1371/journal.pone.0204367. eCollection 2018.

15.

Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.

Sorrentino ZA, Xia Y, Funk C, Riffe CJ, Rutherford NJ, Ceballos Diaz C, Sacino AN, Price ND, Golde TE, Giasson BI, Chakrabarty P.

Neurobiol Dis. 2018 Dec;120:98-106. doi: 10.1016/j.nbd.2018.09.005. Epub 2018 Sep 6.

PMID:
30195075
16.

TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease.

Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, Funk CC, Cruz PE, Allen M, Yaroshenko M, Wang X, Younkin C, Reddy J, Lohrer B, Mehrke L, Moore BD, Liu X, Ceballos-Diaz C, Rosario AM, Medway C, Janus C, Li HD, Dickson DW, Giasson BI, Price ND, Younkin SG, Ertekin-Taner N, Golde TE.

J Exp Med. 2018 Sep 3;215(9):2247-2264. doi: 10.1084/jem.20180484.

17.

Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.

Pace MC, Xu G, Fromholt S, Howard J, Crosby K, Giasson BI, Lewis J, Borchelt DR.

Acta Neuropathol. 2018 Dec;136(6):919-938. doi: 10.1007/s00401-018-1895-y. Epub 2018 Aug 23.

18.

Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts.

Ayers JI, Riffe CJ, Sorrentino ZA, Diamond J, Fagerli E, Brooks M, Galaleldeen A, Hart PJ, Giasson BI.

J Virol. 2018 Aug 29;92(18). pii: e00586-18. doi: 10.1128/JVI.00586-18. Print 2018 Sep 15.

19.

Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis.

Rayaprolu S, Seven YB, Howard J, Duffy C, Altshuler M, Moloney C, Giasson BI, Lewis J.

Mol Cell Neurosci. 2018 Oct;92:17-26. doi: 10.1016/j.mcn.2018.05.009. Epub 2018 Jun 1.

PMID:
29859891
20.

Differential induction of mutant SOD1 misfolding and aggregation by tau and α-synuclein pathology.

Pace MC, Xu G, Fromholt S, Howard J, Giasson BI, Lewis J, Borchelt DR.

Mol Neurodegener. 2018 May 18;13(1):23. doi: 10.1186/s13024-018-0253-9.

21.

Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.

Croft CL, Moore BD, Ran Y, Chakrabarty P, Levites Y, Golde TE, Giasson BI.

PLoS One. 2018 Apr 2;13(4):e0195211. doi: 10.1371/journal.pone.0195211. eCollection 2018.

22.

Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Strang KH, Croft CL, Sorrentino ZA, Chakrabarty P, Golde TE, Giasson BI.

J Biol Chem. 2018 Mar 23;293(12):4579. doi: 10.1074/jbc.AAC118.002657. No abstract available.

23.

Adsorption and decontamination of α-synuclein from medically and environmentally-relevant surfaces.

Phan HTM, Bartz JC, Ayers J, Giasson BI, Schubert M, Rodenhausen KB, Kananizadeh N, Li Y, Bartelt-Hunt SL.

Colloids Surf B Biointerfaces. 2018 Jun 1;166:98-107. doi: 10.1016/j.colsurfb.2018.03.011. Epub 2018 Mar 9.

24.

Locomotor differences in mice expressing wild-type human α-synuclein.

Giraldo G, Brooks M, Giasson BI, Janus C.

Neurobiol Aging. 2018 May;65:140-148. doi: 10.1016/j.neurobiolaging.2018.01.020. Epub 2018 Feb 6.

25.

Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Strang KH, Croft CL, Sorrentino ZA, Chakrabarty P, Golde TE, Giasson BI.

J Biol Chem. 2018 Feb 16;293(7):2408-2421. doi: 10.1074/jbc.M117.815357. Epub 2017 Dec 19. Erratum in: J Biol Chem. 2018 Mar 23;293(12 ):4579.

26.

Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.

Tayebi N, Parisiadou L, Berhe B, Gonzalez AN, Serra-Vinardell J, Tamargo RJ, Maniwang E, Sorrentino Z, Fujiwara H, Grey RJ, Hassan S, Blech-Hermoni YN, Chen C, McGlinchey R, Makariou-Pikis C, Brooks M, Ginns EI, Ory DS, Giasson BI, Sidransky E.

Mol Genet Metab. 2017 Dec;122(4):198-208. doi: 10.1016/j.ymgme.2017.11.001. Epub 2017 Nov 21.

27.

Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice.

Rutherford NJ, Dhillon JS, Riffe CJ, Howard JK, Brooks M, Giasson BI.

Hum Mol Genet. 2017 Dec 15;26(24):4906-4915. doi: 10.1093/hmg/ddx371.

28.

Prion-like transmission of α-synuclein pathology in the context of an NFL null background.

Rutherford NJ, Brooks M, Riffe CJ, Gorion KM, Howard JK, Dhillon JS, Giasson BI.

Neurosci Lett. 2017 Nov 20;661:114-120. doi: 10.1016/j.neulet.2017.09.054. Epub 2017 Sep 28.

29.

A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.

Dhillon JS, Riffe C, Moore BD, Ran Y, Chakrabarty P, Golde TE, Giasson BI.

PLoS One. 2017 Sep 14;12(9):e0184731. doi: 10.1371/journal.pone.0184731. eCollection 2017.

30.

The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome.

Park HJ, Ryu D, Parmar M, Giasson BI, McFarland NR.

PLoS One. 2017 Sep 6;12(9):e0184262. doi: 10.1371/journal.pone.0184262. eCollection 2017.

31.

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.

Strang KH, Goodwin MS, Riffe C, Moore BD, Chakrabarty P, Levites Y, Golde TE, Giasson BI.

Acta Neuropathol Commun. 2017 Jul 31;5(1):58. doi: 10.1186/s40478-017-0458-0.

32.

Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.

Sorrentino ZA, Brooks MMT, Hudson V 3rd, Rutherford NJ, Golde TE, Giasson BI, Chakrabarty P.

Mol Neurodegener. 2017 May 29;12(1):40. doi: 10.1186/s13024-017-0182-z.

33.

Prion-like Spreading in Tauopathies.

Ayers JI, Giasson BI, Borchelt DR.

Biol Psychiatry. 2018 Feb 15;83(4):337-346. doi: 10.1016/j.biopsych.2017.04.003. Epub 2017 Apr 13. Review.

34.

Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.

Koller EJ, Brooks MM, Golde TE, Giasson BI, Chakrabarty P.

Mol Neurodegener. 2017 Jan 3;12(1):1. doi: 10.1186/s13024-016-0142-z.

35.

Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils.

Ayers JI, Brooks MM, Rutherford NJ, Howard JK, Sorrentino ZA, Riffe CJ, Giasson BI.

J Virol. 2017 Jan 3;91(2). pii: e02095-16. doi: 10.1128/JVI.02095-16. Print 2017 Jan 15.

36.

Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes.

Rutherford NJ, Brooks M, Giasson BI.

Acta Neuropathol Commun. 2016 Aug 8;4(1):80. doi: 10.1186/s40478-016-0357-9.

37.

Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology.

Sacino AN, Brooks MM, Chakrabarty P, Saha K, Khoshbouei H, Golde TE, Giasson BI.

J Neurochem. 2017 Feb;140(4):662-678. doi: 10.1111/jnc.13743. Epub 2016 Aug 19.

38.

Propagation of Aβ, tau and α-synuclein pathology between experimental models and human reality: prions, propagons and propaganda.

Uchihara T, Giasson BI, Paulus W.

Acta Neuropathol. 2016 Jan;131(1):1-3. doi: 10.1007/s00401-015-1517-x. No abstract available.

PMID:
26715564
39.

Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology.

Sacino AN, Ayers JI, Brooks MM, Chakrabarty P, Hudson VJ 3rd, Howard JK, Golde TE, Giasson BI, Borchelt DR.

Acta Neuropathol. 2016 Jan;131(1):151-4. doi: 10.1007/s00401-015-1505-1. Epub 2015 Nov 5. No abstract available.

40.

Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.

Uchihara T, Giasson BI.

Acta Neuropathol. 2016 Jan;131(1):49-73. doi: 10.1007/s00401-015-1485-1. Epub 2015 Oct 7. Review.

41.

Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice.

Rutherford NJ, Sacino AN, Brooks M, Ceballos-Diaz C, Ladd TB, Howard JK, Golde TE, Giasson BI.

Mol Neurodegener. 2015 Jul 30;10:32. doi: 10.1186/s13024-015-0029-4.

42.

Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.

Hamm M, Bailey R, Shaw G, Yen SH, Lewis J, Giasson BI.

J Neurosci Res. 2015 Oct;93(10):1567-80. doi: 10.1002/jnr.23614. Epub 2015 Jun 30.

43.

Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.

Chakrabarty P, Hudson VJ III, Sacino AN, Brooks MM, D'Alton S, Lewis J, Golde TE, Giasson BI.

Acta Neuropathol. 2015 Aug;130(2):303-5. doi: 10.1007/s00401-015-1444-x. Epub 2015 May 16. No abstract available.

44.

The A53E α-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture.

Rutherford NJ, Giasson BI.

Neurosci Lett. 2015 Jun 15;597:43-8. doi: 10.1016/j.neulet.2015.04.022. Epub 2015 Apr 17.

45.

Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.

Fishbein I, Kuo YM, Giasson BI, Nussbaum RL.

Brain. 2014 Dec;137(Pt 12):3235-47. doi: 10.1093/brain/awu291. Epub 2014 Oct 27.

46.

Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker.

Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE, Giasson BI.

J Neurosci. 2014 Sep 10;34(37):12368-78. doi: 10.1523/JNEUROSCI.2102-14.2014.

47.

Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice.

Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10732-7. doi: 10.1073/pnas.1321785111. Epub 2014 Jul 7.

48.

Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.

Rutherford NJ, Moore BD, Golde TE, Giasson BI.

J Neurochem. 2014 Dec;131(6):859-67. doi: 10.1111/jnc.12806. Epub 2014 Jul 21.

49.

A cellular system that degrades misfolded proteins and protects against neurodegeneration.

Guo L, Giasson BI, Glavis-Bloom A, Brewer MD, Shorter J, Gitler AD, Yang X.

Mol Cell. 2014 Jul 3;55(1):15-30. doi: 10.1016/j.molcel.2014.04.030. Epub 2014 May 29.

50.

Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.

Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey NH, Rutherford NJ, Ceballos-Diaz C, Robertson J, Golde TE, Giasson BI.

Acta Neuropathol. 2014 May;127(5):645-65. Erratum in: Acta Neuropathol. 2014 Dec;128(6):897-8.

Supplemental Content

Loading ...
Support Center